4538 — Fuso Pharmaceutical Industries Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapValue Trap

Annual income statement for Fuso Pharmaceutical Industries, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	49,632	51,015	55,407	60,563	62,307
Cost of Revenue
Gross Profit	13,397	13,740	13,839	16,533	15,995
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	47,793	48,819	53,583	65,183	59,670
Operating Profit	1,839	2,196	1,824	-4,620	2,637
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,911	2,205	1,767	-4,970	2,438
Provision for Income Taxes
Net Income After Taxes	1,484	1,606	1,378	-3,288	2,012
Net Income Before Extraordinary Items
Net Income	1,484	1,606	1,378	-3,288	2,012
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,483	1,605	1,377	-3,288	2,011
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	177	184	173	281	236
Dividends per Share